BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-5817 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-5817\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07238647-188@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:HRS-5817: Phase 1 readout est. (NCT07238647)
DESCRIPTION:HRS-5817\, phase 1\, Obesity.\nStudy: A Trial of HRS-5817 in Ob
 ese Participants\nEstimated primary completion: 30 January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/hrs-5817#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07238647
URL:https://assetmemo.bio/drug/hrs-5817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934408-188@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-5817: Phase 1 readout est. (NCT06934408)
DESCRIPTION:HRS-5817\, phase 1\, Obesity.\nStudy: A Phase I Study to Evalua
 te the Safety\, Tolerability\, Pharmacokinetics and Pharmacodynamics of HR
 S-5817 Injection\nEstimated primary completion: April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-5817#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06934408
URL:https://assetmemo.bio/drug/hrs-5817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
